{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T15:47:06Z","timestamp":1765295226032,"version":"3.37.3"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s11926-021-01001-1","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T15:59:09Z","timestamp":1619625549000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["JAK Inhibitors for Axial Spondyloarthritis: What does the Future Hold?"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3718-171X","authenticated-orcid":false,"given":"Nurullah","family":"Akkoc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4704-8311","authenticated-orcid":false,"given":"Muhammad A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"key":"1001_CR1","doi-asserted-by":"publisher","unstructured":"Wilson HM, Barker RN. Cytokines. eLS. 2013. https:\/\/doi.org\/10.1002\/9780470015902.a0000929.pub3.","DOI":"10.1002\/9780470015902.a0000929.pub3"},{"key":"1001_CR2","doi-asserted-by":"publisher","unstructured":"Zhang H, Shi N, Diao Z, Chen Y, Zhang Y. Therapeutic potential of TNF\u03b1 inhibitors in chronic inflammatory disorders: past and future. Genes & Diseases. 2020. https:\/\/doi.org\/10.1016\/j.gendis.2020.02.004.","DOI":"10.1016\/j.gendis.2020.02.004"},{"key":"1001_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1749-6632.2009.05159.x","volume":"1182","author":"R Goldbach-Mansky","year":"2009","unstructured":"Goldbach-Mansky R. Blocking interleukin-1 in rheumatic diseases. Ann N Y Acad Sci. 2009;1182:111\u201323. https:\/\/doi.org\/10.1111\/j.1749-6632.2009.05159.x.","journal-title":"Ann N Y Acad Sci."},{"issue":"6","key":"1001_CR4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","volume":"16","author":"EH Choy","year":"2020","unstructured":"Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020;16(6):335\u201345. https:\/\/doi.org\/10.1038\/s41584-020-0419-z.","journal-title":"Nat Rev Rheumatol."},{"issue":"1","key":"1001_CR5","doi-asserted-by":"publisher","first-page":"102429","DOI":"10.1016\/j.autrev.2019.102429","volume":"19","author":"JMG Ruiz de Morales","year":"2020","unstructured":"Ruiz de Morales JMG, Puig L, Dauden E, et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: an updated review of the evidence focusing in controversies. Autoimmun Rev. 2020;19(1):102429. https:\/\/doi.org\/10.1016\/j.autrev.2019.102429.","journal-title":"Autoimmun Rev"},{"key":"1001_CR6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1600-065X.2008.00700.x","volume":"226","author":"L Lyakh","year":"2008","unstructured":"Lyakh L, Trinchieri G, Provezza L, Carra G, Gerosa F. Regulation of interleukin-12\/interleukin-23 production and the T-helper 17 response in humans. Immunol Rev. 2008;226:112\u201331. https:\/\/doi.org\/10.1111\/j.1600-065X.2008.00700.x.","journal-title":"Immunol Rev."},{"issue":"2","key":"1001_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.40728","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Gensler LS, Sieper J, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2019;71(2):258\u201370. https:\/\/doi.org\/10.1002\/art.40728.","journal-title":"Arthritis Rheumatol."},{"issue":"9","key":"1001_CR8","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","volume":"77","author":"D Baeten","year":"2018","unstructured":"Baeten D, Ostergaard M, Wei JC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018;77(9):1295\u2013302. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213328.","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"1001_CR9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1136\/ard.2004.023176","volume":"64","author":"H Haibel","year":"2005","unstructured":"Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis. 2005;64(2):296\u20138. https:\/\/doi.org\/10.1136\/ard.2004.023176.","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"1001_CR10","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1136\/annrheumdis-2013-204963","volume":"74","author":"J Sieper","year":"2015","unstructured":"Sieper J, Braun J, Kay J, et al. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis. 2015;74(6):1051\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204963.","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"1001_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/annrheumdis-2013-203559","volume":"73","author":"J Sieper","year":"2014","unstructured":"Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis. 2014;73(1):95\u2013100. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203559.","journal-title":"Ann Rheum Dis."},{"issue":"5","key":"1001_CR12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","volume":"77","author":"S Banerjee","year":"2017","unstructured":"Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77(5):521\u201346. https:\/\/doi.org\/10.1007\/s40265-017-0701-9.","journal-title":"Drugs."},{"issue":"12","key":"1001_CR13","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1021\/jm401490p","volume":"57","author":"JD Clark","year":"2014","unstructured":"Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023\u201338. https:\/\/doi.org\/10.1021\/jm401490p.","journal-title":"J Med Chem."},{"issue":"12","key":"1001_CR14","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/pro.3519","volume":"27","author":"R Morris","year":"2018","unstructured":"Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK\/STAT pathway. Protein Sci. 2018;27(12):1984\u20132009. https:\/\/doi.org\/10.1002\/pro.3519.","journal-title":"Protein Sci."},{"issue":"12","key":"1001_CR15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843\u201362. https:\/\/doi.org\/10.1038\/nrd.2017.201.","journal-title":"Nat Rev Drug Discov."},{"issue":"1","key":"1001_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228(1):273\u201387. https:\/\/doi.org\/10.1111\/j.1600-065X.2008.00754.x.","journal-title":"Immunol Rev."},{"issue":"2","key":"1001_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1136\/annrheumdis-2017-211555","volume":"77","author":"KF Baker","year":"2018","unstructured":"Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn\u2019s disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175\u201387. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211555.","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"1001_CR18","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/ni.3691","volume":"18","author":"AV Villarino","year":"2017","unstructured":"Villarino AV, Kanno Y, O'Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18(4):374\u201384. https:\/\/doi.org\/10.1038\/ni.3691.","journal-title":"Nat Immunol."},{"issue":"9","key":"1001_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11926-020-00931-6","volume":"22","author":"V Reddy","year":"2020","unstructured":"Reddy V, Cohen S. JAK inhibitors: what is new? Curr Rheumatol Rep. 2020;22(9):50. https:\/\/doi.org\/10.1007\/s11926-020-00931-6.","journal-title":"Curr Rheumatol Rep."},{"issue":"3","key":"1001_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.semarthrit.2017.04.005","volume":"47","author":"A Deodhar","year":"2017","unstructured":"Deodhar A, Yu D. Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. Semin Arthritis Rheum. 2017;47(3):343\u201350. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.04.005.","journal-title":"Semin Arthritis Rheum."},{"issue":"3","key":"1001_CR21","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","volume":"76","author":"J Sieper","year":"2017","unstructured":"Sieper J, Deodhar A, Marzo-Ortega H, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Ann Rheum Dis. 2017;76(3):571\u201392. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210023.","journal-title":"Ann Rheum Dis."},{"issue":"8","key":"1001_CR22","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017;76(8):1340\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210322.","journal-title":"Ann Rheum Dis."},{"key":"1001_CR23","unstructured":"Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of adult patients with ankylosing spondylitis: primary analysis of a phase 3, randomized, double-blind, placebo-controlled study [abstract]. Arthritis Rheumatol. 2020;72(suppl 10)."},{"issue":"10214","key":"1001_CR24","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","volume":"394","author":"D van der Heijde","year":"2019","unstructured":"\u2022\u2022 van der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial. Lancet. 2019;394(10214):2108\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(19)32534-6This multicentre, randomised, double-blind, placebo-controlled, two-period, parallel-group, phase 2\/3 study shows that upadacitinib is effective in supressing the signs and symptoms of AS, and also the inflammation in the spine and sacroiliac joints on MRI.","journal-title":"Lancet."},{"issue":"10162","key":"1001_CR25","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"\u2022 van der Heijde D, Baraliakos X, Gensler LS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10162):2378\u201387. https:\/\/doi.org\/10.1016\/S0140-6736(18)32463-2This article presents the results of the Phase II TORTUGA trial which investigated the efficacy and safety of filgotinib for the treatment of patients with active ankylosing spondylitis and suggests that filgotinib shows good efficacy across a wide range of parameters relevant for ankylosing spondylitis.","journal-title":"Lancet."},{"key":"1001_CR26","unstructured":"van der Heijde D, Song IH, Pangan A, et al. Efficacy and safety of upadacitinib in a randomized, double-blind, placebo-controlled, multicenter phase 2\/3 clinical study of patients with active ankylosing spondylitis. Arthritis & Rheumatology. 2019;71."},{"key":"1001_CR27","unstructured":"Abbvie Inc. RINVOQTM (upadacitinib): US prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211675s000lbl.pdf."},{"key":"1001_CR28","unstructured":"Abbvie Inc. RINVOQ (upadacitinib). EPAR-Product Information 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rinvoq-epar-product-information_en.pdf. Accessed April 10 2021."},{"key":"1001_CR29","doi-asserted-by":"crossref","unstructured":"Deodhar A, van der Heijde D, Sieper J, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis: 1-year results from a randomized, double-blind, placebo-controlled study with open-label extension [abstract]. Arthritis Rheumatol. 2020;72(Suppl 10).","DOI":"10.1002\/art.41911"},{"key":"1001_CR30","unstructured":"Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca\u00ae (Filgotinib). Press release. December 15, 2020. https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2020\/12\/gilead-and-galapagos-announce-new-commercialization-and-development-agreement-for-jyseleca-filgotinib. Accessed 20 Dec 2020."},{"key":"1001_CR31","doi-asserted-by":"publisher","unstructured":"Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020;6(3). https:\/\/doi.org\/10.1136\/rmdopen-2020-001395.","DOI":"10.1136\/rmdopen-2020-001395"},{"key":"1001_CR32","doi-asserted-by":"crossref","unstructured":"Cohen SB, Van Vollenhoven R, Curtis JR, et al. Safety profile of upadacitinib up to 3 years of exposure in patients with rheumatoid arthritis [abstract]. Arthritis Rheumatol. 2020;72(Suppl 10).","DOI":"10.1136\/annrheumdis-2020-eular.2396"},{"issue":"4","key":"1001_CR33","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","volume":"13","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234\u201343. https:\/\/doi.org\/10.1038\/nrrheum.2017.23.","journal-title":"Nat Rev Rheumatol."},{"key":"1001_CR34","doi-asserted-by":"publisher","unstructured":"Angelini J, Talotta R, Roncato R, et al. JAK-inhibitors for the treatment of rheumatoid arthritis: a focus on the present and an outlook on the future. Biomolecules. 2020;10(7). https:\/\/doi.org\/10.3390\/biom10071002.","DOI":"10.3390\/biom10071002"},{"key":"1001_CR35","doi-asserted-by":"publisher","unstructured":"\u2022 Sunzini F, McInnes I, Siebert S. JAK inhibitors and infections risk: focus on herpes zoster. Ther Adv Musculoskelet Dis. 2020;12:1759720X20936059. https:\/\/doi.org\/10.1177\/1759720X20936059A concise review which presents the current evidence on the principal JAK inhibitors and their association with viral infections.","DOI":"10.1177\/1759720X20936059"},{"issue":"12","key":"1001_CR36","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s40265-020-01349-1","volume":"80","author":"M Harigai","year":"2020","unstructured":"Harigai M, Honda S. Selectivity of Janus kinase inhibitors in rheumatoid arthritis and other immune-mediated inflammatory diseases: is expectation the root of all headache? Drugs. 2020;80(12):1183\u2013201. https:\/\/doi.org\/10.1007\/s40265-020-01349-1.","journal-title":"Drugs."},{"issue":"3","key":"1001_CR37","doi-asserted-by":"publisher","first-page":"e001370","DOI":"10.1136\/rmdopen-2020-001370","volume":"6","author":"J Kay","year":"2020","unstructured":"Kay J, Harigai M, Rancourt J, et al. Changes in selected haematological parameters associated with JAK1\/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. RMD Open. 2020;6(3):e001370. https:\/\/doi.org\/10.1136\/rmdopen-2020-001370.","journal-title":"RMD Open."},{"key":"1001_CR38","doi-asserted-by":"publisher","unstructured":"Cohen SB, van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2020:annrheumdis-2020-218510. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218510.","DOI":"10.1136\/annrheumdis-2020-218510"},{"key":"1001_CR39","unstructured":"Europen Medicines Agency-Committee for Medicinal Products for Human Use (CHMP). Assessment report. Jyseleca (Filgotinib). 2020. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/jyseleca-epar-public-assessment-report_en.pdf. Accessed 24 Jan 2020."},{"key":"1001_CR40","doi-asserted-by":"publisher","unstructured":"Alvaro-Gracia JM, Garcia-Llorente JF, Valderrama M, Gomez S, Montoro M. Update on the safety profile of tofacitinib in rheumatoid arthritis from clinical trials to real-world studies: a narrative review. Rheumatol Ther. 2020. https:\/\/doi.org\/10.1007\/s40744-020-00258-9.","DOI":"10.1007\/s40744-020-00258-9"},{"issue":"6","key":"1001_CR41","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","volume":"158","author":"PA Olivera","year":"2020","unstructured":"\u2022 Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1554\u201373 e12. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.001A meta-analysis assesing the safety profile of JAK inhibitors in patients with with immune-mediated diseases including ankylosing spondylitis.","journal-title":"Gastroenterology."},{"issue":"7","key":"1001_CR42","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.mayocp.2020.01.039","volume":"95","author":"F Wang","year":"2020","unstructured":"Wang F, Sun L, Wang S, et al. Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis. Mayo Clin Proc. 2020;95(7):1404\u201319. https:\/\/doi.org\/10.1016\/j.mayocp.2020.01.039.","journal-title":"Mayo Clin Proc."},{"issue":"2","key":"1001_CR43","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1016\/s2665-9913(19)30137-7","volume":"2","author":"A Pawar","year":"2020","unstructured":"\u2022 Pawar A, Desai RJ, Gautam N, Kim SC. Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study. The Lancet Rheumatology. 2020;2(2):e84\u201398. https:\/\/doi.org\/10.1016\/s2665-9913(19)30137-7This is a multidatabase cohort study which compares the risk of admission to hospital for serious infection and individual seirous infection types including herpes zoster in patients with rheumatoid arthritis initiating tofacitinib versus one of the seven bDMARDs.","journal-title":"The Lancet Rheumatology."},{"issue":"10","key":"1001_CR44","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","volume":"75","author":"JR Curtis","year":"2016","unstructured":"Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1843\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209131.","journal-title":"Ann Rheum Dis."},{"issue":"10","key":"1001_CR45","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","volume":"58","author":"K Bechman","year":"2019","unstructured":"Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019;58(10):1755\u201366. https:\/\/doi.org\/10.1093\/rheumatology\/kez087.","journal-title":"Rheumatology (Oxford)."},{"issue":"7","key":"1001_CR46","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1080\/14740338.2020.1774550","volume":"19","author":"F Cantini","year":"2020","unstructured":"\u2022 Cantini F, Blandizzi C, Niccoli L, Petrone L, Goletti D. Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases. Expert Opin Drug Saf. 2020;19(7):861\u201372. https:\/\/doi.org\/10.1080\/14740338.2020.1774550A systematic review on the risk of active tuberculosis occurrence in patients receiving JAK inhibitors.","journal-title":"Expert Opin Drug Saf."},{"issue":"7","key":"1001_CR47","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s40264-018-0651-5","volume":"41","author":"IC Scott","year":"2018","unstructured":"Scott IC, Hider SL, Scott DL. Thromboembolism with Janus kinase (JAK) inhibitors for rheumatoid arthritis: how real is the risk? Drug Saf. 2018;41(7):645\u201353. https:\/\/doi.org\/10.1007\/s40264-018-0651-5.","journal-title":"Drug Saf."},{"issue":"9","key":"1001_CR48","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s40264-020-00973-w","volume":"43","author":"F Ibrahim","year":"2020","unstructured":"Ibrahim F, Scott DL. Thromboembolism and Janus kinase inhibitors. Drug Saf. 2020;43(9):831\u20133. https:\/\/doi.org\/10.1007\/s40264-020-00973-w.","journal-title":"Drug Saf."},{"key":"1001_CR49","unstructured":"FDA Drug Safety Communication. FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR). US Food and Drug Administration. www.fda.gov\/drugs\/drug-safety-and-availability\/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and. Accessed 29 Dec 2020."},{"key":"1001_CR50","unstructured":"Pfizer Inc. XELJANZ (Tofacitinib). EPAR-Product Information. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xeljanz-epar-product-information_en.pdf. Accessed 29 Dec 2020."},{"issue":"4","key":"1001_CR51","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s40264-017-0622-2","volume":"41","author":"A Verden","year":"2018","unstructured":"Verden A, Dimbil M, Kyle R, Overstreet B, Hoffman KB. Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors. Drug Saf. 2018;41(4):357\u201361. https:\/\/doi.org\/10.1007\/s40264-017-0622-2.","journal-title":"Drug Saf."},{"issue":"8","key":"1001_CR52","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1136\/annrheumdis-2018-214846","volume":"78","author":"W Xie","year":"2019","unstructured":"Xie W, Huang Y, Xiao S, Sun X, Fan Y, Zhang Z. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis. 2019;78(8):1048\u201354. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214846.","journal-title":"Ann Rheum Dis."},{"key":"1001_CR53","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Yates M, Mootoo A, Adas M, et al. Venous thromboembolism risk with JAK inhibitors: a meta-analysis. Arthritis Rheumatol. 2020. https:\/\/doi.org\/10.1002\/art.41580.","DOI":"10.1002\/art.41580"},{"issue":"11","key":"1001_CR54","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","volume":"79","author":"P Mease","year":"2020","unstructured":"\u2022 Mease P, Charles-Schoeman C, Cohen S, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis. 2020;79(11):1400\u201313. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216761A detailed analysis assesing the risk of deep vein thrombosis, pulmonary embolism, venous thromboembolism and arterial thromboembolism from the tofacitinib RA, PsA and PsO development programmes and observational studies.","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"1001_CR55","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","volume":"80","author":"P Nash","year":"2021","unstructured":"\u2022\u2022 Nash P, Kerschbaumer A, Dorner T, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2021;80(1):71\u201387. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218398A useful consensus document providing an assessment of evidence for efficacy and safety of an JAKis with guidance on issues of practical management.","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 1","key":"1001_CR56","doi-asserted-by":"publisher","first-page":"150.1","DOI":"10.1136\/annrheumdis-2020-eular.2823","volume":"79","author":"E Vallejo-Yag\u00fce","year":"2020","unstructured":"Vallejo-Yag\u00fce E, Weiler S, Burden AM. Op0237 thromboembolic safety profile of tofacitinib and baricitinib: an analysis of who vigibase. Annals of the Rheumatic Diseases. 2020;79(Suppl 1):150.1. https:\/\/doi.org\/10.1136\/annrheumdis-2020-eular.2823.","journal-title":"Annals of the Rheumatic Diseases."},{"issue":"1","key":"1001_CR57","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","volume":"21","author":"J Wollenhaupt","year":"2019","unstructured":"Wollenhaupt J, Lee EB, Curtis JR, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019;21(1):89. https:\/\/doi.org\/10.1186\/s13075-019-1866-2.","journal-title":"Arthritis Res Ther."},{"key":"1001_CR58","unstructured":"Pfizer shares co-primary endpoint results from post-marketing required safety study of XELJANZ\u00ae (tofacitinib) in subjects with rheumatoid arthritis (RA). https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-shares-co-primary-endpoint-results-post-marketing. Accessed 2 Mar 2021."},{"key":"1001_CR59","unstructured":"Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib). https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/initial-safety-trial-results-find-increased-risk-serious-heart-related-problems-and-cancer-arthritis. Accessed 2 Mar 2021."},{"issue":"10","key":"1001_CR60","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599\u2013613. https:\/\/doi.org\/10.1002\/art.41042.","journal-title":"Arthritis Rheumatol."},{"key":"1001_CR61","unstructured":"Pfizer Inc. XELJANZ\u00ae (tofacitinib) [package insert]. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213082s000lbl.pdf. Accessed 29 Dec 2020."},{"issue":"16","key":"1001_CR62","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377(16):1537\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1615975.","journal-title":"N Engl J Med."},{"issue":"16","key":"1001_CR63","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377(16):1525\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1615977.","journal-title":"N Engl J Med."},{"key":"1001_CR64","doi-asserted-by":"publisher","unstructured":"Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2020:annrheumdis-2020-218870. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218870.","DOI":"10.1136\/annrheumdis-2020-218870"},{"issue":"4","key":"1001_CR65","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/bjd.14018","volume":"173","author":"KA Papp","year":"2015","unstructured":"Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015;173(4):949\u201361. https:\/\/doi.org\/10.1111\/bjd.14018.","journal-title":"Br J Dermatol."},{"issue":"6","key":"1001_CR66","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","volume":"66","author":"J Panes","year":"2017","unstructured":"Panes J, Sandborn WJ, Schreiber S, et al. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017;66(6):1049\u201359. https:\/\/doi.org\/10.1136\/gutjnl-2016-312735.","journal-title":"Gut."},{"issue":"Supplement_2","key":"1001_CR67","doi-asserted-by":"publisher","first-page":"S746","DOI":"10.1093\/ecco-jcc\/jjz186","volume":"14","author":"G Rogler","year":"2020","unstructured":"Rogler G. Efficacy of JAK inhibitors in Crohn\u2019s disease. J Crohns Colitis. 2020;14(Supplement_2):S746\u2013S54. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz186.","journal-title":"J Crohns Colitis."},{"issue":"10066","key":"1001_CR68","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","volume":"389","author":"S Vermeire","year":"2017","unstructured":"Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389(10066):266\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(16)32537-5.","journal-title":"Lancet."},{"issue":"3","key":"1001_CR69","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10067-019-04875-w","volume":"39","author":"E Miserocchi","year":"2020","unstructured":"Miserocchi E, Giuffre C, Cornalba M, Pontikaki I, Cimaz R. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol. 2020;39(3):847\u201351. https:\/\/doi.org\/10.1007\/s10067-019-04875-w.","journal-title":"Clin Rheumatol."}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-021-01001-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-021-01001-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-021-01001-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,25]],"date-time":"2022-12-25T18:54:15Z","timestamp":1671994455000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-021-01001-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":69,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1001"],"URL":"https:\/\/doi.org\/10.1007\/s11926-021-01001-1","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"type":"print","value":"1523-3774"},{"type":"electronic","value":"1534-6307"}],"subject":[],"published":{"date-parts":[[2021,4,28]]},"assertion":[{"value":"23 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nurullah Akkoc: Consulting and\/or speaking fees from UCB and speaking fees from Amgen. Muhammad A Khan: Receipt of consultation fees from AbbVie, Novartis, and Lilly and from speaker\u2019s bureaus of AbbVie and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"34"}}